Wednesday, 07 December 2022


Shanghai Henlius Biotech strengthens presence in lung cancer drug market

04 November 2022 | News

Henlius' novel anti-PD-1 mAb HANSIZHUANG (Serplulimab) receives NMPA approval for the treatment of sqNSCLC

Image credit: freepik

Image credit: freepik

Shanghai Henlius Biotech has announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC), has been approved by the National Medical Products Administration (NMPA), providing an alternative treatment option for patients.

HANSIZHUANG had already been approved for the treatment of Microsatellite Instability-High (MSI-H) solid tumours, and it covers a wide variety of indications to benefit a broader population of patients.

Lung cancer is one of the most common cancers in the world, and it is the malignant tumour with the highest morbidity and mortality in China. According to the latest national cancer statistics released by the National Cancer Center, there are 828,000 new cases of lung cancer, with a total death toll of 657,000, in which NSCLC accounts for about 80% - 85% of all lung cancers, and about 50% of NSCLC patients are in local advanced stage that is not suitable for surgical resection or have metastasized at the time of diagnosis.

Wenjie Zhang, Chairman, Executive Director, and CEO of Henlius, said, “the approval marks that HANSIZHUANG steps into the clinical practice of lung cancer, benefiting patients with its world-class quality, and actively expands its presence. Lung cancer is a kind of cancer with high incidence in China and world, which has a huge demand for clinical treatment. Henlius has a sound indication plan in a diverse variety of lung cancer, in which many clinical studies are forging ahead. We will fully tap the potential of HANSIZHUANG and look forward to more positive study results to make further contributions in cancer treatment.”

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account